mTOR inhibitors as potential therapeutics for endometriosis: A narrative review DOI Creative Commons

Akiko Nakamura,

Yuji Tanaka, Tsukuru Amano

и другие.

Molecular Human Reproduction, Год журнала: 2024, Номер unknown

Опубликована: Ноя. 21, 2024

Abstract Mammalian target of rapamycin (mTOR) inhibitors have been used clinically as anticancer and immunosuppressive agents for over 20 years, demonstrating their safety after long-term administration. These exhibit various effects, including inhibition cell proliferation, interaction with the oestrogen progesterone pathways, immunosuppression, regulation angiogenesis, control autophagy. We evaluated potential mTOR therapeutic endometriosis, examined secondary benefits related to reproductive function, assessed how side effects can be managed. conducted a thorough review publications on role pathway effectiveness in endometriosis patients. results indicate that is activated endometriosis. Additionally, shown efficacy monotherapies They may alleviate resistance hormonal therapy suggesting synergistic effect when combination therapy. The include decreased miscarriage rates, improved implantation, prevention age-related follicular loss ovarian hyperstimulation syndrome. Activation has also implicated malignant transformation Preclinical studies suggest dosage needed treating lower than required or therapy, potentially reducing dosage-dependent effects. In conclusion, while inhibitors, which allow pregnancy during oral administration, show clinical use all stages current evidence limited preclinical studies, further research confirm effectiveness.

Язык: Английский

mTOR inhibitors as potential therapeutics for endometriosis: A narrative review DOI Creative Commons

Akiko Nakamura,

Yuji Tanaka, Tsukuru Amano

и другие.

Molecular Human Reproduction, Год журнала: 2024, Номер unknown

Опубликована: Ноя. 21, 2024

Abstract Mammalian target of rapamycin (mTOR) inhibitors have been used clinically as anticancer and immunosuppressive agents for over 20 years, demonstrating their safety after long-term administration. These exhibit various effects, including inhibition cell proliferation, interaction with the oestrogen progesterone pathways, immunosuppression, regulation angiogenesis, control autophagy. We evaluated potential mTOR therapeutic endometriosis, examined secondary benefits related to reproductive function, assessed how side effects can be managed. conducted a thorough review publications on role pathway effectiveness in endometriosis patients. results indicate that is activated endometriosis. Additionally, shown efficacy monotherapies They may alleviate resistance hormonal therapy suggesting synergistic effect when combination therapy. The include decreased miscarriage rates, improved implantation, prevention age-related follicular loss ovarian hyperstimulation syndrome. Activation has also implicated malignant transformation Preclinical studies suggest dosage needed treating lower than required or therapy, potentially reducing dosage-dependent effects. In conclusion, while inhibitors, which allow pregnancy during oral administration, show clinical use all stages current evidence limited preclinical studies, further research confirm effectiveness.

Язык: Английский

Процитировано

3